info@PremierEndpoint.com (914) 315-9334

The University of Texas MD Anderson Cancer Center and pharmaceutical giant Pfizer say they’ll jointly evaluate new combinations of three investigational immunotherapies and other agents to treat various solid tumors and blood cancers. The clinical agreement covers five studies, for now. An MD Anderson/Pfizer joint steering committee will oversee the initiative. Pfizer’s investigational therapies to […]

FALLS CHURCH, Va., Oct. 5, 2017 /PRNewswire-USNewswire/ — Inova Schar Cancer Institute announced today it is recruiting patients for the American Society of Clinical Oncology’s (ASCO) first-ever clinical trial, the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. The trial will evaluate molecularly targeted cancer drugs and collect data on clinical outcomes to learn about […]

Tuebingen, Germany and Houston, Texas, October 4, 2017 – Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financing, raising $58 million. The Series E funding was supported by existing investors including dievini Hopp Biotech holding, Wellington Partners, AT Impf GmbH and others. This latest financing […]

HOUSTON, Oct. 3, 2017 /PRNewswire/ — ImmunoMet Therapeutics, a private biotechnology company focused on utilizing cellular metabolism to develop novel anti-tumor and immuno-oncology therapies, today announced that the Company has initiated its Phase 1 clinical study for IM156, a potent oxidative phosphorylation (OXPHOS) inhibitor. This is a dose escalation study designed to evaluate the safety […]

Four months after two Endocyte drug candidates stumbled in early-stage studies, sparking a corporate shakeup, the company has signed a deal landing an experimental prostate cancer treatment that it says is ready for Phase 3 clinical trials. West Lafayette, IN-based Endocyte (NASDAQ: ECYT) says it paid $12 million up front to German biochemicals company ABX […]

For the second time in just over six months, there’s a newcomer in a next-generation class of breast cancer-fighters. Thursday, U.S. regulators greenlighted Eli Lilly’s Verzenio, better known as abemaciclib. The drug will join a pair of HR-postive, HER2-negative meds in Pfizer’s Ibrance and Novartis’ Kisqali, the latter of which won its own FDA approval […]

NewLink inks deal with AstraZeneca to test Imfinzi combo
September 28, 2017

Dive Brief: NewLink Genetics Corp. has hooked up with AstraZeneca plc to study the safety and efficacy of combining its small molecule IDO pathway inhibitor, indoximod, with the British pharma’s anti-PD-L1 antibody Imfinzi in metastatic pancreatic cancer. Through a three-arm, mid-stage study, the companies will assess the combo treatment plus standard of care chemotherapy compared […]

SAN DIEGO, Sept. 27, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented an overview of the comprehensive immune monitoring data from the Phase 2 Investigator Sponsored Trial led by the University of California, San Francisco (UCSF) at the 2nd World Congress on Electroporation and Pulsed […]

Even as it battles against knockoffs of its own biologic drugs, Amgen is steadily growing its own biosimilar portfolio of copies of some of the bestselling cancer and inflammation drugs. Now, with a co-development deal with Simcere, Amgen is taking that effort to China, a country relying heavily on copycat drugs. The exclusive agreement includes […]

Bristol Myers Squibb’s Opdivo has won another approval—and the right to take on Bayer in liver cancer. Friday, the FDA cleared the immuno-oncology standout in patients with the most common type of liver cancer who’ve already been treated with Bayer’s Nexavar. The accelerated approval came on the back of positive overall response and duration of […]

1 2 3 18